The leaders of Metabolic Solutions Development Company are frequently asked to speak on diabetes, insulin sensitizers and metabolic diseases associated with age-related mitochondrial dysfunction. Supporting materials from select presentations are listed below.
22nd Annual BioCenturty Future Leaders in the Biotech Industry Conference, New York 2015 Presentation includes an overview of the Company’s development plans for its lead compound, MSDC- 0602, which is expected to enter into large Phase 2b clinical trials in 2015 in patients diagnosed with NASH and polycystic kidney disease (PKD), respectively.March 20, 2015 - 2:30 PM ET
Data presented to date suggest that the mTOT protein complex functions as a molecular "sensor switch" connecting mitochondrial metabolism to important cellular activities perturbed in age-related metabolic diseases such as type 2 diabetes, including insulin sensitivity. MSDC's novel pharmaceutical agents selectively bind and modulate proteins in the mTOT complex, effecting pyruvate utilization and resulting in improved insulin action, lipid oxidation, preservation of beta cell function, and generation of brown fat.
Type 2 diabetes is a metabolic disorder affecting the ways in which the body uses various nutrients for growth and energy. The root cause of this disorder is insulin resistance, which is a result of the body's inability to efficiently and effectively convert glucose - a simple sugar made from the food you eat - to energy. Insulin, a hormone produced by the beta cells in the pancreas, aids in the transfer of glucose into the bloodstream, where it is used or metabolized by cells for growth and energy. Diabetes results when changes in metabolism alter both the ability of insulin to work on its target tissues and the ability of the beta cells to make and secrete insulin.
Copyright © 2019 Metabolic Solutions Development Company - All Rights Reserved.